爱尔眼科(300015) - 2017 Q4 - 年度业绩

Financial Performance - Total revenue for 2017 reached RMB 5,950,764,985.81, an increase of 48.75% compared to RMB 4,000,401,671.18 in 2016[4] - Net profit attributable to shareholders was RMB 739,700,827.26, up 32.80% from RMB 556,990,786.78 in the previous year[4] - Basic earnings per share increased to RMB 0.4869, reflecting a growth of 30.43% compared to RMB 0.3733 in 2016[4] - Net profit after deducting non-recurring gains and losses was RMB 772,157,286.02, an increase of 41.35% from RMB 546,282,478.48 in 2016[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 9,392,874,911.57, a 112.13% increase from RMB 4,427,969,970.44 at the beginning of the period[4] - Shareholders' equity attributable to the company reached RMB 5,216,735,709.76, up 70.87% from RMB 3,053,094,885.69 at the start of the year[4] - The company's net asset per share at the end of the period was RMB 3.29, an increase of 8.94% from RMB 3.02 at the beginning of the year[4] Return on Equity - The weighted average return on equity was 21.79%, a slight decrease of 0.05 percentage points from the previous year[4] Strategic Implementation - The company successfully implemented its internationalization strategy, contributing to rapid growth in treatment volume and operational efficiency[6] Performance Consistency - There were no discrepancies between the reported performance and the previously announced earnings forecast for 2017[7]